Packard BioScience
This article was originally published in The Gray Sheet
Executive Summary
Maker of instruments and related consumables for the life sciences research market, including drug discovery, genomics and biochip analysis, files for an initial public offering. Packard's primary products include microwell plate readers, imaging systems, automated liquid handling systems, laboratory robotics systems, bioanalytical spectrometers and biochemicals and related supplies. The IPO proceeds are tabbed for debt repayment, R&D and general corporate purposes. The Meriden, Connecticut firm recorded 1999 revenues of $264.9 mil., up 16.1%. A net loss of $198,000 compares to net income of $1.9 mil. in 1998. Underwriters include Merrill Lynch, Chase H&Q, and Robert Baird & Co
You may also be interested in...
Packard BioScience
Maker of instruments and related consumables for the life sciences research market, including drug discovery, genomics and biochip analysis, goes public April 20 via an initial offering of 12 mil. shares at $9 each and grosses $108 mil. The proceeds are tabbed for debt repayment, R&D, and general corporate purposes (1"The Gray Sheet" April 3, p. 22). Underwriters include Merrill Lynch, Chase H&Q, Robert Baird & Co., Banc of America Securities, and Thomas Weisel Partners
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.